ArticleVeterinary sciences2025
Metabolic Profiling, Tissue Distribution, and Tolerance Assessment of Bopu Powder in Laying Hens Following Long-Term Dietary Administration.
Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to elucidate the metabolic profile and safety of Bopu Powder in laying hens, focusing on its principal alkaloids protopine (PRO) and allocryptopine (ALL). Nine hens received intravenous PRO (1 mg/kg·bw), ALL (1 mg/kg·bw), or saline. Blood (5-120 min post-dose) and feces (48 h collection) were analyzed via LC-Q-TOF-MS, revealing 9 ALL and 12 PRO metabolites, including two novel structures. In a separate 56-day trial, 324 hens were assigned to control, 50 mg/kg Bopu Powder (BP), or 500 mg/kg Bopu Powder (BPX) groups. Post-trial analyses showed PRO and ALL residues primarily in their kidneys (BP: PRO 11.21 ng/g, ALL 6.59 ng/g; BPX: PRO 23.62 ng/g, ALL 7.92 ng/g) and livers (BP: PRO 15.52 ng/g; BPX: PRO 269.49 ng/g, ALL 56.14 ng/g). Residues in eggs occurred exclusively in the BPX group (PRO 26.86 ng/g, ALL 12.29 ng/g). No residues were detected in other tissues (jejunum, ileum, ovaries, oviducts, uterus, muscle, fat, gizzard). Serum biochemical indicators and histopathological examinations were used to evaluate the long-term effects of Bopu Powder. The results confirmed that supplementation at doses up to 500 mg/kg did not induce any significant physiological or histopathological alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.